Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 25.5 -2.63% -0.69
ADMS closed down 2.63 percent on Thursday, June 21, 2018, on 82 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADMS trend table...

Date Alert Name Type % Chg
Jun 21 Lower Bollinger Band Walk Weakness 0.00%
Jun 21 Inside Day Range Contraction 0.00%
Jun 21 Oversold Stochastic Weakness 0.00%
Jun 20 Lower Bollinger Band Walk Weakness -2.63%
Jun 20 Lower Bollinger Band Touch Weakness -2.63%
Jun 20 Oversold Stochastic Weakness -2.63%
Jun 19 Below Lower BB Weakness 0.91%
Jun 19 Down 3 Days in a Row Weakness 0.91%
Jun 19 Lower Bollinger Band Touch Weakness 0.91%
Jun 19 Oversold Stochastic Weakness 0.91%

Older signals for ADMS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Is ADMS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 44.0
52 Week Low 13.5
Average Volume 654,949
200-Day Moving Average 28.4136
50-Day Moving Average 28.6038
20-Day Moving Average 27.5785
10-Day Moving Average 26.717
Average True Range 1.1313
ADX 31.24
+DI 13.32
-DI 25.44
Chandelier Exit (Long, 3 ATRs ) 27.5661
Chandelier Exit (Short, 3 ATRs ) 28.4239
Upper Bollinger Band 29.9195
Lower Bollinger Band 25.2375
Percent B (%b) 0.06
BandWidth 16.976993
MACD Line -0.9198
MACD Signal Line -0.6522
MACD Histogram -0.2676
Fundamentals Value
Market Cap 574.11 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -8.53
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.06
Resistance 3 (R3) 27.20 26.82 26.80
Resistance 2 (R2) 26.82 26.42 26.75 26.71
Resistance 1 (R1) 26.16 26.18 25.97 26.02 26.63
Pivot Point 25.78 25.78 25.69 25.71 25.78
Support 1 (S1) 25.12 25.38 24.93 24.98 24.37
Support 2 (S2) 24.74 25.14 24.67 24.29
Support 3 (S3) 24.08 24.74 24.20
Support 4 (S4) 23.94